{"protocolSection":{"identificationModule":{"nctId":"NCT06667908","orgStudyIdInfo":{"id":"90301900NSC2001"},"secondaryIdInfos":[{"id":"90301900NSC2001","type":"OTHER","domain":"Janssen Research & Development, LLC"},{"id":"2024-518276-32-00","type":"REGISTRY","domain":"EUCT number"}],"organization":{"fullName":"Johnson & Johnson Enterprise Innovation Inc.","class":"INDUSTRY"},"briefTitle":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC","acronym":"CONVERGE"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-12-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2028-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-10-30","studyFirstSubmitQcDate":"2024-10-30","studyFirstPostDateStruct":{"date":"2024-10-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-09","lastUpdatePostDateStruct":{"date":"2025-10-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Johnson & Johnson Enterprise Innovation Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer."},"conditionsModule":{"conditions":["Carcinoma, Non-Small-Cell Lung"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":130,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1: Cohort A and Cohort B","type":"EXPERIMENTAL","description":"Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (cohort A: 22% gross tumor volume \\[GTV\\] and cohort B: 33% GTV) along with cCRT (concurrent chemotherapy with radiation therapy) followed by consolidation immunotherapy (cIT) to evaluate feasibility of JNJ-90301900 injection procedure.","interventionNames":["Drug: JNJ-90301900","Biological: Durvalumab","Radiation: Concurrent Chemo/Radiation Therapy (cCRT)","Drug: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin","Drug: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel"]},{"label":"Part 2: Arm A and Arm B","type":"EXPERIMENTAL","description":"Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (Arm A: 22% GTV and Arm B: 33% GTV) along with cCRT followed by cIT to evaluate the efficacy and safety of JNJ-90301900.","interventionNames":["Drug: JNJ-90301900","Biological: Durvalumab","Radiation: Concurrent Chemo/Radiation Therapy (cCRT)","Drug: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin","Drug: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel"]},{"label":"Part 2: Arm C: (Control treatment)","type":"ACTIVE_COMPARATOR","description":"Participants will receive treatment with cCRT followed by cIT as control treatment to evaluate the efficacy and safety of JNJ-90301900.","interventionNames":["Biological: Durvalumab","Radiation: Concurrent Chemo/Radiation Therapy (cCRT)","Drug: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin","Drug: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel"]}],"interventions":[{"type":"DRUG","name":"JNJ-90301900","description":"JNJ-90301900 will be injected intratumorally and/or intranodally.","armGroupLabels":["Part 1: Cohort A and Cohort B","Part 2: Arm A and Arm B"]},{"type":"BIOLOGICAL","name":"Durvalumab","description":"Durvalumab will be administered as intravenous (IV) infusion as cIT.","armGroupLabels":["Part 1: Cohort A and Cohort B","Part 2: Arm A and Arm B","Part 2: Arm C: (Control treatment)"]},{"type":"RADIATION","name":"Concurrent Chemo/Radiation Therapy (cCRT)","description":"Radiation by intensity modulated radiation therapy (IMRT) will be administered.","armGroupLabels":["Part 1: Cohort A and Cohort B","Part 2: Arm A and Arm B","Part 2: Arm C: (Control treatment)"]},{"type":"DRUG","name":"Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin","description":"Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.","armGroupLabels":["Part 1: Cohort A and Cohort B","Part 2: Arm A and Arm B","Part 2: Arm C: (Control treatment)"]},{"type":"DRUG","name":"Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel","description":"Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.","armGroupLabels":["Part 1: Cohort A and Cohort B","Part 2: Arm A and Arm B","Part 2: Arm C: (Control treatment)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment","description":"ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments.","timeFrame":"Up to 2 Years and 2 months"}],"secondaryOutcomes":[{"measure":"Disease Response Rate (ORR) Post-cCRT and Pre-cIT","description":"Disease response rate is defined as percentage of participants who achieve CR or PR, post-concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) and pre-consolidation immunotherapy (cIT) based on investigator's assessment according to RECIST v1.1.","timeFrame":"Up to 12 Weeks"},{"measure":"Disease Control Rate (DCR) Post-cCRT and Pre-cIT","description":"DCR is defined as percentage of participants who achieve CR, PR and stable disease post-cCRT and pre-cIT based on investigator's assessment according to RECIST v1.1.","timeFrame":"Up to 12 Weeks"},{"measure":"Objective Response Rate (ORR) as Assessed by the Investigator","description":"ORR is defined as the percentage of participants who have a best response of CR or PR using RECIST v1.1 as assessed by the investigator.","timeFrame":"Up to 2 Years and 2 months"},{"measure":"Progression Free Survival (PFS)","description":"PFS is defined as the time from the enrollment/randomization until disease progression or death due to any cause according to RECIST v1.1.","timeFrame":"Up to 2 Years and 2 months"},{"measure":"Duration of Response (DoR)","description":"DoR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first.","timeFrame":"Up to 2 Years and 2 months"},{"measure":"Time to Locoregional Failure (LRF)","description":"Time to LRF is defined as the time from enrollment/randomization to the first LRF using ICR assessments.","timeFrame":"Up to 2 Years and 2 months"},{"measure":"Time to Distant Failure (DF)","description":"Time to DF is defined as the time from enrollment/randomization to the first DF using ICR assessments.","timeFrame":"Up to 2 Years and 2 months"},{"measure":"Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment","description":"TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose of study treatment received plus 30 days or prior to the start of subsequent anticancer therapy (non-durvalumab), whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent anticancer therapy, or any AE that is considered treatment-related regardless of the start date of the event. TEAEs related to JNJ-90301900 injection procedure, JNJ-90301900, RT, ChT, or cIT will be reported.","timeFrame":"Up to 2 Years and 2 months"},{"measure":"Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities","description":"Participants with laboratory parameters, physical examination, vital signs including ECOG performance status abnormalities will be reported.","timeFrame":"Up to 2 Years and 2 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening\n* Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization\n* Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification\n* Have at least 1 target lesion (primary lung lesion or involved lymph node\\[s\\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression\n* Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV\n* Another concurrent or prior primary malignancy within the last 36 months at informed consent\n* Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab\n* History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Contact","role":"CONTACT","phone":"844-434-4210","email":"Participate-In-This-Study1@its.jnj.com"}],"overallOfficials":[{"name":"Johnson & Johnson Enterprise Innovation Inc. Clinical Trial","affiliation":"Johnson & Johnson Enterprise Innovation Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Connecticut Health Center","status":"RECRUITING","city":"Farmington","state":"Connecticut","zip":"06030","country":"United States","geoPoint":{"lat":41.71982,"lon":-72.83204}},{"facility":"Orlando Health Cancer Institute","status":"RECRUITING","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Emory University Winship Cancer Institute","status":"RECRUITING","city":"Atlanta","state":"Georgia","zip":"30306","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"NYU Langone Health","status":"RECRUITING","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","status":"RECRUITING","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University of North Carolina at Chapel Hill","status":"RECRUITING","city":"Chapel Hill","state":"North Carolina","zip":"27514","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"FirstHealth of the Carolinas","status":"RECRUITING","city":"Pinehurst","state":"North Carolina","zip":"28374","country":"United States","geoPoint":{"lat":35.19543,"lon":-79.46948}},{"facility":"University of Pennsylvania","status":"RECRUITING","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"MD Anderson Cancer Center","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Vermont Medical Center","status":"RECRUITING","city":"Burlington","state":"Vermont","zip":"05401","country":"United States","geoPoint":{"lat":44.47588,"lon":-73.21207}},{"facility":"Macquarie University","status":"RECRUITING","city":"North Ryde","zip":"2109","country":"Australia","geoPoint":{"lat":-33.79677,"lon":151.12436}},{"facility":"Royal Melbourne Hospital","status":"RECRUITING","city":"Parkville","zip":"3050","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","status":"RECRUITING","city":"São Paulo","zip":"05651 901","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Hopital De La Cavale Blanche","status":"RECRUITING","city":"Brest","zip":"29200","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Hopital Nord Marseille","status":"RECRUITING","city":"Marseille","zip":"13015","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Hopital Tenon","status":"RECRUITING","city":"Paris","zip":"75020","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Prince of Wales Hospital","status":"RECRUITING","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Radboud Umcn","status":"RECRUITING","city":"Nijmegen","zip":"6525 GA","country":"Netherlands","geoPoint":{"lat":51.8425,"lon":5.85278}},{"facility":"Hosp. Univ. 12 de Octubre","status":"RECRUITING","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Clinica Univ. de Navarra","status":"RECRUITING","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Hosp. Clinico Univ. de Santiago","status":"RECRUITING","city":"Santiago de Compostela","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"Hosp. Univ. I Politecni La Fe","status":"RECRUITING","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Sakarya University Training and Research Hospital","status":"RECRUITING","city":"Sakarya","zip":"54100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.50333,"lon":32.07583}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of Johnson \\& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.","url":"https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-10-31"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"D011878","term":"Radiotherapy"}],"ancestors":[{"id":"D013812","term":"Therapeutics"}]}},"hasResults":false}